Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation

This is the first report demonstrating a predictive value of SLC19A1 genotypes for the outcome of DAV regimen followed by autologous transplantation in MM patients. These findings might have a significant impact on the management of MM patients, as alternative drug combinations become available. Therefore, we conclude that genetic variability may influence the outcome of MM therapy and pharmacogenetics may provide a tool for improving individualization of the therapy. However, the results cannot be generalized, as prognostic factors identified for a specific protocol can be of less importance for other protocols.